Entrada Therapeutics, Inc. (TRDA)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Collaboration revenue | - | 20,558 | 19,570 | 94,694 |
| Research and development | - | 32,074 | 31,257 | 32,035 |
| General and administrative | - | 10,274 | 9,971 | 9,236 |
| Total operating expenses | - | 42,348 | 41,228 | 41,271 |
| (loss) income from operations | - | -21,790 | -21,658 | 53,423 |
| Interest and other income | - | 4,441 | 5,766 | 4,366 |
| Total other income | - | 4,441 | 5,766 | 4,366 |
| (loss) income before provision for income taxes | -42,925 | -17,349 | -15,892 | 57,789 |
| Provision for income taxes | 178 | - | -1,860 | 2,758 |
| Net (loss) income | -43,103 | -17,349 | -14,032 | 55,031 |
| Unrealized (loss) gain on marketable securities | -37 | 480 | 1,301 | -83 |
| Total other comprehensive (loss) income | -37 | 480 | 1,301 | -83 |
| Total comprehensive (loss) income | -43,140 | -16,869 | -12,731 | 54,948 |
| Net (loss) income per share, basic (in dollars per share) | -1.04 | -0.42 | -0.35 | 1.61 |
| Net (loss) income per share, diluted (in dollars per share) | -1.04 | -0.42 | -0.35 | 1.55 |
| Weighted-average common shares outstanding, basic (in shares) | 41,338,752 | 41,073,732 | 40,629,602 | 34,180,549 |
| Weighted-average common shares outstanding, diluted (in shares) | 41,338,752 | 41,073,732 | 40,629,602 | 35,507,029 |